Noteworthily, a majority of solid tumors exhibited decreased MARCO expression compared with the controls, including bladder cancer, colon cancer, cholangiocarcinoma, lung cancer, HCC, ovarian cancer, prostate cancer, breast cancer, adrenocortical carcinoma, esophageal cancer, gastric cancer, endometrial cancer, and uterine sarcoma (Figure 5B). This evidence concerns the gene MARCO and prostate carcinoma.